News & Media

202420232022202120202019201820172016201520142013
Press release 2023/11/07 Regulatory
Medivir announces a partially guaranteed rights issue of approximately SEK 148 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF...

Read more
Press release 2023/10/27 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2023

“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line...

Read more
Press release 2023/10/25
Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Read more
Press release 2023/10/23
Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Read more
Press release 2023/10/20 Regulatory
Change in Medivir's Board of Directors

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/10/05
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13...

Read more
Press release 2023/09/14
Medivir to present at the Pareto Securities Healthcare Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/09/11
Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/09/07
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

Read more
Press release 2023/09/04 Regulatory
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Central review of the 6 patients in phase 1b dose escalation part was performed In these 6 patients, complete response was...

Read more
Press release 2023/09/01
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/08/23
Medivir to present at the Erik Penser Bank Company Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more